I have over 25 years experience in the Pharmaceutical industry discovering and developing therapeutic antibodies, small molecule and more recently oligonucleotides. After obtaining a degree in Biochemistry from Oxford University and a PhD in Drug Metabolism from London University I worked as a Post Doc on the optimisation and pharmacology of ricin immunotoxins at the ICRF in London. In 1987 I joined AstraZeneca where I initially worked on the development of early generation antibody therapeutics as well as leading small molecule drug projects. For a number of years I also had a science leadership role within AstraZeneca in the area of therapeutic vascular modulation having championed the area within the company. More recently I championed the establishment and scientific management of AstraZeneca’s first major antibody collaboration with Abgenix/Amgen that led to a number of clinical development candidates. In my current role as Chief Scientist in the Oncology iMed I have leadership roles in evaluation of new approaches and technologies. Over the last few years I led a global cross therapy area team on oligonucleotide based therapies and championed the area to senior management within AZ. I currently have leadership roles in collaborations with ISIS, Regulus and Moderna and spend the majority of my time supporting and championing the oligoncleotide area within AZ. I have over 50 peer reviewed publications where I am lead or co-author and have published and presented on my work at conferences throughout my career at AstraZeneca.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.